New treatment offers hope
It provides measurable clinical benefit for patients short of breath
Tiny valve is a breath of fresh air
Late-stage emphysema is a type of chronic obstructive pulmonary disease (COPD). While there is no cure, treatment can help …
Patient breathing easy after procedure
A RINGWOOD father says he has been given his life back after a revolutionary procedure helped treat his emphysema.
Pulmonx Names New Chief Executive Officer
December 18, 2015, Redwood City, California – Pulmonx Corporation, a leader in interventional pulmonology, today announced that Glen French has joined the company as President, Chief Executive Officer and member of the Board of Directors.
Mr. French posesses deep experience leading and transforming…
New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Medical Device for Emphysema
New England Journal of Medicine Publishes Groundbreaking Study Demonstrating Benefits of Medical Device for Emphysema
First Prospective, Randomized Controlled Study Using the Chartis System to Select Patients Confirms Clinical Superiority of Zephyr® EBV Therapy over Medical Management in Treating Emphysema
Redwood City, Calif. – December 9, 2015 – Pulmonx Corporation, a leader in interventional pulmonology,…
Pulmonx Starts UK Clinical Trial at Royal Brompton Hospital with Minimally Invasive Lung Valve Treatment Offering Hope to Emphysema Patients
London, UK, October 28, 2015 – A clinical trial recently commenced at Royal Brompton Hospital to evaluate a minimally-invasive valve based treatment that may help patients suffering from severe emphysema breathe easier without surgery.
Emphysema is a form of chronic obstructive pulmonary disease…
Pulmonx Launches Chartis Tablet, Simplifying Patient Selection For Zephyr® Endobronchial Valve Therapy
REDWOOD CITY, Calif. – September 28, 2015 – Pulmonx®, a leader in interventional pulmonology, today announced the launch of a tablet version of its Chartis Pulmonary Assessment System, a diagnostic tool designed to identify optimal patients for Zephyr® Endobronchial Valve (EBV) therapy. The Chartis…
Pulmonx’s Zephyr® Endobronchial Valve Demonstrates Statistically and Clinically Significant Results in a Prospective, Randomized Controlled Trial
September 09, 2014, Redwood City & Munich – The results of BeLieVeR-HIFi trial, the first double-blinded, randomized, controlled clinical trial to assess the impact of the Zephyr® Endobronchial Valve (EBV) for the treatment of emphysema, were presented today at the 2014 European Respiratory Society…
Lancet Publication of Sham-Controlled Clinical Trial Shows Pulmonx’s Zephyr® Endobronchial Valves Deliver Significant Benefit to Emphysema Patients
REDWOOD CITY, Calif. – July 1, 2015 –Pulmonx®, a leader in interventional pulmonology, today announced publication in The Lancet of results from the BeLieVeR-HIFi clinical trial, the first successful sham-controlled trial of any minimally invasive emphysema device.
BeLieVeR-HIFi is a prospective,…
Zephyr® Endobronchial Valves from Pulmonx® shown to Benefit Severe Emphysema Patients with Homogeneous Disease
Denver, Colo. – May 18, 2015 –Pulmonx®, a leader in interventional pulmonology, today announced results from a retrospective analysis of the landmark VENT trial that demonstrated a statistically significant benefit in severe emphysema patients with homogeneous disease that received treatment with…